SecBot SecBot
SECBOTREPLAY Home › Report › NVAX

NVAX · Novavax reported Q2 2026 total revenue of $57M, a 76% decline YoY from…

NOVAVAX INC · 8-K filed Aug 6, 2026 at 08:03 ET

At the news

NEUTRALIMPACT 5/10

8-K filed Aug 6, 2026 at 08:03 ET

Novavax reported Q2 2026 total revenue of $57M, a 76% decline YoY from $239M, driven by the absence of a $175M BLA milestone and $27M Takeda amendment that benefited the prior year. The company posted a GAAP net loss of $53M ($-0.32 per share) versus net income of $107M in Q2 2025. However, Novavax raised its full-year 2026 Adjusted Total Revenue framework to $235M-$275M (from $230M-$270M) and improved GAAP combined R&D and SG&A expense guidance, signaling confidence in its partnership-driven strategy and cost discipline despite the quarterly revenue drop.

  • Q2 2026 total revenue was $57M, down 76% YoY from $239M.
  • GAAP net loss of $53M ($-0.32 per share) vs net income of $107M ($0.66) in Q2 2025.
  • EPS of $-0.32 beat consensus of $-0.38 by 16.6%.
  • Raised full-year 2026 Adjusted Total Revenue guidance to $235M-$275M from $230M-$270M.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access